Eli Lilly picks up another Covid-19 EUA as regulators wave through its Olumiant plus remdesivir combo

Eli Lilly has picked up another win at the FDA, crossing the finish line again in the Covid-19 treatment race despite some mixed data. And the authorization comes before Regeneron’s antibody therapy, which notably was used to treat President Donald Trump back in October, could pick up an EUA.